IP Library › Patent Application 10976371
Patent Application
App. No. 10/976,371

Recombinant stabilizer botulinum toxin pharmaceutical compositions

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/976,371
Abstract

A botulinum toxin pharmaceutical formulation free of animal derived proteins, comprising a botulinum toxin and a recombinant albumin, suitable for therapeutic administration to a human patient, and methods for treating patients with various diseases and afflictions with the formulation.

Claims (24)

1 . A pharmaceutical composition, comprising:

(a) a botulinum toxin, and;

(b) a recombinant stabilizer.

2 . The pharmaceutical composition of claim 1 , wherein the botulinum toxin is present as a botulinum toxin complex.

3 . The pharmaceutical composition of claim 1 wherein the botulinum toxin is present as a pure botulinum toxin.

4 . The pharmaceutical composition of claim 1 , wherein the recombinant stabilizer is selected from the group consisting of a recombinant albumin, a recombinant collagen and a recombinant gelatin

5 . The pharmaceutical composition of claim 1 , further comprising a secondary stabilizer.

6 . The pharmaceutical composition of claim 5 wherein the secondary stabilizer comprises a metal.

7 . The pharmaceutical composition of claim 6 wherein the metal is zinc.

8 . The pharmaceutical composition of claim 5 wherein the secondary stabilizer is NAT.

9 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition has an enhanced potency or stability.

10 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition has an enhanced anti-microbial activity.

11 . The pharmaceutical composition of claim 1 , wherein the recombinant stabilizer is a recombinant albumin.

12 . The pharmaceutical composition of claim 1 , wherein the botulinum toxin is selected from the group consisting of botulinum toxins types A, B, C, D, E, and F.

13 . A pharmaceutical composition, comprising:

(a) a botulinum toxin type A, and;

(b) a recombinant albumin.

14 . (canceled)

15 . A pharmaceutical composition, comprising

(a) a botulinum toxin

(b) a primary stabilizer, and;

(c) and a secondary stabilizer, wherein the secondary stabilizer is a metal.

16 . The pharmaceutical composition of claim 13 wherein the pharmaceutical composition has an enhanced antimicrobial activity.

17 - 19 . (canceled)